Rank 43 • Biotech & Discovery
Paige.ai
Develops AI-powered diagnostic software and digital pathology viewers to assist pathologists in identifying cancer and complex diseases.
Visit website- Signal Score
- 88.5
- Total raised
- $220M
- Stage
- Series C
- Founded
- 2017
- Headquarters
- New York, USA
- Region
- North America
Their signal
As an early recipient of FDA de novo clearance for AI-based digital pathology, Paige.ai is deeply integrated into global oncology workflows, enhancing diagnostic speed and accuracy.
Signal Score 88.5editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.